BNET Industries
Market Cap:$149.2B
Last Fiscal Year Sales:$48.4B
- Public
- US
Dow Jones Description
Taking care of you and your four-legged friends too! Pfizer Inc. (NYSE: PFE), based in New York, NY, discovers, develops, manufactures and sells prescription medications for humans and animals. Employing about 115,000 people, this $51.3 billion company operates in three segments: Human Health, Consumer Healthcare and Animal Health. Together, these segments cover treatments for diseases such as cardiovascular and metabolic diseases, medications for oral care, tobacco dependence, and products for prevention and treatment of diseases in livestock and pets.
Number of Employees 81,800
Peer Companies
NAICS Code Pharmaceutical Preparation Manufacturing: 325412
Recent Events
-
Bristol-Myers Squibb Raises Exchange Offer Price For Mead Johnson Shares - Update
-
'IT boosts efficiency & innovation'
-
Inspector General Saved Billions in Healthcare This Year
-
Pfizer and B.C. launch $9M collaboration to tackle cancer
-
Reportlinker Adds Growth Factors Blood And Tissue - A World Report
-
Pfizer signs agreement with Protalix BioTherapeutics for Taliglucerase alfa
-
Pfizer Inc. PFE JOBS Acquires Rights to Protalix Biotherapeutics's Gaucher Drug in Deal Worth $115M
-
Roche's Merger Formula for Genentech
-
Pfizer PFE Will Not Renew Ethical Distribution Agreement Term with MWI Veterinary Supply MWIV
-
Pfizer Inc. and Wyeth; Analysis of Agreement Containing Consent Order To Aid Public Comment and...
-
A 2nd Loss for Pfizer in Drug Suits
-
Pfizer acquires stem cell therapies assets of Axordia
-
Standpoint Raised Its FY10 Price Target on Pfizer PFE to $24
-
ImmunoVaccine signs exclusive licence deal with Pfizer
-
Pfizer Animal Health selects Bader Rutter as agency of record
-
FDA panel backs Pfizer's anti-infection vaccine for kids
-
Cash Just Kept On Piling Up, But It Looks Like The Spending Has Started
-
Goldman Sachs Said Pfizer PFE Best Positioned US Pharma in China
News & Analysis
Filter by
collaboration and pfizer inc. - All News and Analysis
Grameen Health to Establish Independent Collaborations with Pfizer, GE Healthcare, and Mayo Clinic to Create Sustainable Healthcare Delivery Models for the Developing World
- 2008-09-24
Partnerships Will Support Development of Business Models That Meet the Health Needs of 4 Billion People Around the World Who Live on Annual Incomes of Less Than $3,000 BOSTON -- Grameen Health, an affiliate of Grameen Bank, the pioneering micro-financing organization in Bangladesh that shared the Nobel Peace Prize...
FivePrime and Pfizer Enter Oncology and Diabetes Collaboration
- 2008-05-20
SAN FRANCISCO -- Five Prime Therapeutics, Inc. and Pfizer Inc. (NYSE:PFE) today announced the initiation of a worldwide collaborative research and license agreement. The collaboration will focus on the discovery of antibody targets and novel therapeutic protein products to treat certain areas of cancer and diabetes. Under the collaboration, FivePrime...
Linguamatics Announces Expansion of Strategic Collaboration with Pfizer
- 2008-04-16
* Pfizer expands use of NLP-based knowledge discovery platform, Linguamatics I2E, for text mining across R&D
Source MDx Announces Translational Molecular Medicine Collaboration With Pfizer
- 2007-12-27
Source MDx, Inc. today announced a multi-year translational molecular medicine collaboration with Pfizer, Inc. to develop and validate RNA-based pharmacodynamic and predictive biomarkers within Pfizer's cancer and inflammation therapeutic development programs. This molecular diagnostics collaboration will combine Pfizer's expertise in genomic profiling with Source MDx's expertise in RNA transcription...
Pfizer and Adolor Enter into Exclusive Worldwide Collaboration to Develop and Commercialize Novel Pain Compounds
- 2007-12-05
Proprietary Delta Opioid Receptor Agonists Offer Promise to Treat Range of Inflammatory, Neuropathic and Acute Pain Conditions
Pfizer and Bristol-Myers Squibb Finalize Agreement for Worldwide Collaboration on Metabolic Disorders Program
- 2007-08-27
Companies Will Jointly Conduct Phase III Development and Commercialization of DGAT-1 Inhibitor Compounds
Icagen Announces Alliance with Pfizer in Ion Channel-Focused Therapeutics for Pain and Related Disorders
- 2007-08-14
RESEARCH TRIANGLE PARK, N.C. -- Icagen, Inc. (NASDAQ: ICGN) today announced that it has entered into a worldwide collaboration and licensing agreement with Pfizer for the discovery, development and commercialization of compounds which modulate three specific sodium ion channels as new potential treatments for pain and related disorders. Under the...
Hydra Biosciences and Pfizer Global Research & Development Sign Collaboration Agreement
- 2007-07-26
-- Leverages Hydra's Proprietary Ion Channel Technology in the Area of Pain -
Cambria Biosciences Announces Collaboration with Pfizer Animal Health in Antiparasitic Drug Discovery
- 2007-06-07
WOBURN, Mass. -- Cambria Biosciences LLC, a Boston-area CNS drug discovery company, today announced a research collaboration agreement with Pfizer Animal Health to guide the discovery and development of new classes of safe and effective antiparasitic drug products.
Bristol-Myers Squibb and Pfizer Announce Worldwide Collaboration to Develop and Commercialize Anticoagulant and Metabolic Compounds
- 2007-04-26
Apixaban Currently in Phase III Trials for Prevention of Venous Thromboembolism and Prevention of Stroke Associated with Atrial Fibrillation
Industry Transcripts by Seeking Alpha
-
Avanir Pharmaceuticals F4Q09 (Qtr End 09/30/2009) Earnings Call Transcript
on Nov 24, 2009about AVNR
-
Palatin Technologies F1Q10 (Qtr End 9/30/09) Earnings Call Transcript
on Nov 16, 2009about PTN
-
Flamel Technologies SA Q3 2009 Earnings Call Transcript
on Nov 16, 2009about FLML
-
NexMed Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about NEXM
-
InterMune, Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about ITMN
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- Teva, In Turnabout, Sues to Protect Its Multiple Sclerosis Drug Copaxone 3 votes
- Fired Whistleblower Reps Make Similar Claim: Pfizer Said They Lacked "Integrity" 3 votes
- More Tysabri Problems; Time for a Biogen-Idec Credibility Check 3 votes
- Biogen Idec's Social Media Ties Save Tysabri Again; FDA Watching 3 votes
